和譽-B(02256):FGFR4抑制劑依帕戈替尼獲FDA快速通道資格,用於治療HCC患者
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
近期的新股基本上就是你敢參與、頂得住壓力...
《經濟通通訊社10日專訊》美股周一(9日...
《經濟通通訊社10日專訊》樂欣戶外(02...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...
Post Content Read Mo...